Kyverna saw an 8-point improvement on the MG-ADL scale, which measures the impact of gMG on daily functions, in the three ...
With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to ...
News-Medical.Net on MSN
Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies
Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...
CAR-T therapies from Cabaletta Bio and Bristol Myers Squibb have induced complete remissions in patients living with a severe ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
“Utilizing real-world data, technology, strategic solutions, and cross-departmental partnerships will help ensure equitable access, so the right member receives the right drug at the right time and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback